Malignant neoplasm of myometrium
ICD-10 C54.2 is a billable code used to indicate a diagnosis of malignant neoplasm of myometrium.
Malignant neoplasm of the myometrium refers to cancer that originates in the muscular layer of the uterus, known as the myometrium. This type of cancer is often classified under uterine sarcomas, which are rare compared to endometrial carcinomas. The myometrium is responsible for the contractions of the uterus during menstruation and childbirth, and malignancies in this area can lead to significant symptoms such as abnormal bleeding, pelvic pain, and pressure symptoms. Diagnosis typically involves imaging studies such as ultrasound or MRI, and histological confirmation through biopsy. Staging of myometrial cancer is crucial for determining treatment options and prognosis, often utilizing the FIGO staging system, which assesses tumor size, depth of invasion, and presence of metastasis. CA-125, a tumor marker, may be elevated in cases of myometrial malignancies, although it is not specific to this type of cancer. Treatment usually involves surgical intervention, such as a hysterectomy, and may be followed by adjuvant therapies including radiation or chemotherapy depending on the stage and grade of the tumor.
Detailed pathology reports, imaging studies, and surgical notes are essential for accurate coding.
Diagnosis and treatment planning for patients with suspected myometrial tumors, staging evaluations, and post-operative follow-ups.
Ensure that all tumor characteristics are documented, including size, grade, and presence of metastasis.
Imaging reports must clearly indicate findings related to the myometrium and any suspicious masses.
Imaging for suspected uterine masses, follow-up imaging post-treatment.
Radiologists should provide detailed descriptions of imaging findings to support coding.
Used for surgical treatment of malignant myometrial tumors.
Operative report detailing the procedure and findings.
Gynecologic oncologists should ensure comprehensive documentation of tumor characteristics.
The primary treatment is surgical, typically involving a total abdominal hysterectomy, possibly followed by adjuvant therapies such as radiation or chemotherapy depending on the stage of the disease.
